{"DataElement":{"publicId":"3439566","version":"2","preferredName":"Prostate Carcinoma Prior Chemotherapy Agent Name","preferredDefinition":"Text name of an agent administered to an individual with prostate carcinoma prior to current treatment.","longName":"PROS_PRIOR_AGT_NM","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3438799","version":"1","preferredName":"Prostate Carcinoma Prior Chemotherapy Administered","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_Earlier in time or order.","longName":"PROST_PRIOR_TX_ADM","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3438797","version":"1","preferredName":"Prostate Carcinoma Prior Chemotherapy","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:Earlier in time or order.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C4863:C25629:C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0A5415-E5E9-6FDD-E040-BB89AD4348BB","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"ONEDATA","dateModified":"2012-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0A5415-E5F7-6FDD-E040-BB89AD4348BB","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3439553","version":"2","preferredName":"Prostate Carcinoma Agent Name","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known.","longName":"PROST_AGT_NM","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"GnRH antagonist","valueDescription":"Gonadotropin Releasing Hormone Antagonist","ValueMeaning":{"publicId":"3441844","version":"1","preferredName":"Gonadotropin Releasing Hormone Antagonist","longName":"3441844","preferredDefinition":"A synthetic peptide that competes with the neurohormone GnRH for its receptor, thus decreasing or blocking GnRH action. As a result endogenous pituitary output of FSH and LH is shut down.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotropin Releasing Hormone Antagonist","conceptCode":"C2092","definition":"Any agent that binds to the gonadotropin releasing hormone receptors and causes both the inhibition of gonadotropin releasing hormone activities and a decrease in the pituitary output of follicle stimulating hormone and luteinizing hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5DBA01-0E1E-B9C6-E040-BB89AD43287F","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-C9BA-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"GnRH agonist","valueDescription":"Gonadotropin-Releasing Hormone Analog Agonist","ValueMeaning":{"publicId":"3441845","version":"1","preferredName":"Gonadotropin-Releasing Hormone Analog Agonist","longName":"3441845","preferredDefinition":"(LOO-tin-eye-zing.AG-o-nist) LH-RH agonist.  A drug that inhibits the secretion of sex hormones.  In men, LH-RH agonist causes testosterone levels to fall.  In women, LH-RH agonist causes the levels of estrogen and other sex hormones to fall.: An gent that has affinity for a receptor and intrinsic activity at that receptor.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotropin-Releasing Hormone Analogue","conceptCode":"C2022","definition":"A hormone made in the laboratory that has the same effect as the gonadotropin-releasing hormone (GnRH) produced naturally by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agonist","conceptCode":"C1514","definition":"An agent that has affinity for a receptor and intrinsic activity at that receptor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5DBA01-0E44-B9C6-E040-BB89AD43287F","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-C9C4-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Sipuleucel-T","valueDescription":"APC8015 Vaccine","ValueMeaning":{"publicId":"3439565","version":"1","preferredName":"APC8015 Vaccine","longName":"3439565v1.00","preferredDefinition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sipuleucel-T","conceptCode":"C1985","definition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1C2E-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"GDEEN","dateModified":"2023-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-C9CE-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Zoledronic Acid","valueDescription":"Zoledronate","ValueMeaning":{"publicId":"2576643","version":"1","preferredName":"Zoledronate","longName":"2576643","preferredDefinition":"A drug that belongs to the family of drugs called bisphosphonates. It is used to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-C9D8-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Ketoconazole","valueDescription":"Ketoconazole","ValueMeaning":{"publicId":"2578210","version":"1","preferredName":"Ketoconazole","longName":"2578210","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-C9EC-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Abiraterone","valueDescription":"Abiraterone","ValueMeaning":{"publicId":"3124284","version":"1","preferredName":"Abiraterone","longName":"3124284v1.00","preferredDefinition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone","conceptCode":"C77333","definition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D692-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-C9F6-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Leuprolide","valueDescription":"Leuprolide","ValueMeaning":{"publicId":"2921029","version":"1","preferredName":"Leuprolide","longName":"2921029","preferredDefinition":"The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leuprolide","conceptCode":"C62042","definition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD78-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA00-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Buserelin","valueDescription":"Buserelin","ValueMeaning":{"publicId":"2576647","version":"1","preferredName":"Buserelin","longName":"2576647","preferredDefinition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buserelin","conceptCode":"C320","definition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F874-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA0A-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Nafarelin","valueDescription":"Nafarelin","ValueMeaning":{"publicId":"3439556","version":"1","preferredName":"Nafarelin","longName":"3439556","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nafarelin","conceptCode":"C61613","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1AF9-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA14-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Histrelin","valueDescription":"Histrelin","ValueMeaning":{"publicId":"3439558","version":"1","preferredName":"Histrelin","longName":"3439558v1.00","preferredDefinition":"A long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histrelin","conceptCode":"C74270","definition":"A long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1B1F-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA1E-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Goserelin","valueDescription":"Goserelin","ValueMeaning":{"publicId":"2921026","version":"1","preferredName":"Goserelin","longName":"2921026","preferredDefinition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin","conceptCode":"C1374","definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD2F-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA28-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Cetrorelix","valueDescription":"Cetrorelix","ValueMeaning":{"publicId":"3439560","version":"1","preferredName":"Cetrorelix","longName":"3439560","preferredDefinition":"Cetrorelix is a synthetic decapeptide which is structurally related to gonadotrophin-releasing hormone (luteinising-hormone releasing hormone).  It acts as an LHRH antagonist. (from ASTA Medica)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetrorelix","conceptCode":"C2481","definition":"Cetrorelix is a synthetic decapeptide which is structurally related to gonadotrophin-releasing hormone (luteinising-hormone releasing hormone).  It acts as an LHRH antagonist. (from ASTA Medica)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1B4F-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA32-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Ganirelix","valueDescription":"Ganirelix","ValueMeaning":{"publicId":"3439562","version":"1","preferredName":"Ganirelix","longName":"3439562","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganirelix","conceptCode":"C77423","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1B75-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA3C-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Abarelix","valueDescription":"Abarelix","ValueMeaning":{"publicId":"2576646","version":"1","preferredName":"Abarelix","longName":"2576646","preferredDefinition":"A peptide antagonist of gonadotropin-releasing hormone. Abarelix binds to the luteinizing hormone-releasing hormone receptor, thereby inhibiting the secretion of gonadotropin releasing hormone and ultimately reducing testosterone production. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abarelix","conceptCode":"C2015","definition":"A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F873-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA46-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Degarelix","valueDescription":"Degarelix","ValueMeaning":{"publicId":"3240855","version":"1","preferredName":"Degarelix","longName":"3240855","preferredDefinition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Degarelix","conceptCode":"C48385","definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4302120-6A24-B554-E040-BB89AD4307C7","latestVersionIndicator":"Yes","beginDate":"2011-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-26","modifiedBy":"COOPERM","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA50-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Flutamide","valueDescription":"Flutamide","ValueMeaning":{"publicId":"3379052","version":"1","preferredName":"Flutamide","longName":"3379052","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-212B-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA5A-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Nilutamide","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"3335142","version":"1","preferredName":"Nilutamide","longName":"3335142","preferredDefinition":"A drug that blocks the effects of male hormones in the body.  It belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ED69-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA64-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Bicalutamide","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA6E-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Finasteride","valueDescription":"Finasteride","ValueMeaning":{"publicId":"2576856","version":"1","preferredName":"Finasteride","longName":"2576856","preferredDefinition":"A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F945-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA78-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Dutasteride","valueDescription":"Dutasteride","ValueMeaning":{"publicId":"2576806","version":"1","preferredName":"Dutasteride","longName":"2576806","preferredDefinition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for conversion of testosterone in the skin and liver. Inhibition of 5-alpha reductase leads to a reduction of dihydrotestosterone formation and subsequently prevents the enlargement of the prostate gland. Dutasteride is used in the treatment of benign prostatic hyperplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dutasteride","conceptCode":"C47503","definition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F913-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA82-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Epristeride","valueDescription":"Epristeride","ValueMeaning":{"publicId":"3439564","version":"1","preferredName":"Epristeride","longName":"3439564","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epristeride","conceptCode":"C81621","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1BEB-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA8C-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CA96-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Denosumab","valueDescription":"Denosumab","ValueMeaning":{"publicId":"3241060","version":"1","preferredName":"Denosumab","longName":"3241060","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A108-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CAA0-E6C9-E040-BB89AD4332B0","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Tasquinimod","valueDescription":"Tasquinimod","ValueMeaning":{"publicId":"3788418","version":"1","preferredName":"Tasquinimod","longName":"3788418","preferredDefinition":"A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tasquinimod","conceptCode":"C74080","definition":"A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB0D-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CB26-E6C9-E040-BB89AD4332B0","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Mitoxantrone","valueDescription":"Mitoxantrone","ValueMeaning":{"publicId":"3518877","version":"1","preferredName":"Mitoxantrone","longName":"3518877","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4110B19-590C-CB86-E040-BB89AD431138","latestVersionIndicator":"Yes","beginDate":"2012-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CAB4-E6C9-E040-BB89AD4332B0","beginDate":"2012-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"BKM120","valueDescription":"PI3K Inhibitor BKM120","ValueMeaning":{"publicId":"3788416","version":"1","preferredName":"PI3K Inhibitor BKM120","longName":"3788416","preferredDefinition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buparlisib","conceptCode":"C90565","definition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CAD3-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CAEC-E6C9-E040-BB89AD4332B0","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Samarium","valueDescription":"Samarium","ValueMeaning":{"publicId":"3379571","version":"1","preferredName":"Samarium","longName":"3379571","preferredDefinition":"Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Samarium","conceptCode":"C0036147","definition":"Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-378E-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CB30-E6C9-E040-BB89AD4332B0","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Alpharadin","valueDescription":"Radium Chloride Ra-223","ValueMeaning":{"publicId":"3788420","version":"1","preferredName":"Radium Chloride Ra-223","longName":"3788420","preferredDefinition":"A radiopharmaceutic of short-lived radium-223 with potential anti-tumor activity. Radium preferentially binds to and accumulates in bone tissue. The radioisotope radium-223 may kill bone cancer cells through the local emission of high energy alpha particles, thereby potentially decreasing tumor progression in the skeleton.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radium Ra 223 Dichloride","conceptCode":"C62535","definition":"A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB3D-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CB56-E6C9-E040-BB89AD4332B0","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Cabazitaxel","valueDescription":"Cabazitaxel","ValueMeaning":{"publicId":"3788422","version":"1","preferredName":"Cabazitaxel","longName":"3788422","preferredDefinition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabazitaxel","conceptCode":"C66937","definition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB63-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF80A1B1-CB7C-E6C9-E040-BB89AD4332B0","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"ONEDATA","dateModified":"2013-06-19","deletedIndicator":"No"},{"value":"Orteronel","valueDescription":"Steroid 17alpha-monooxygenase TAK-700","ValueMeaning":{"publicId":"3259298","version":"1","preferredName":"Steroid 17alpha-monooxygenase TAK-700","longName":"3259298","preferredDefinition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orteronel","conceptCode":"C90582","definition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A939DA44-CB85-3822-E040-BB89AD432672","latestVersionIndicator":"Yes","beginDate":"2011-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E79A8AD1-7C79-EEBC-E040-BB89AD430D6D","beginDate":"2013-06-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-30","modifiedBy":"ONEDATA","dateModified":"2013-09-30","deletedIndicator":"No"},{"value":"Triptorelin","valueDescription":"Triptorelin","ValueMeaning":{"publicId":"3380222","version":"1","preferredName":"Triptorelin","longName":"3380222","preferredDefinition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin","conceptCode":"C1267","definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1517-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E75490CB-9E9A-9630-E040-BB89AD430967","beginDate":"2013-09-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-26","modifiedBy":"ONEDATA","dateModified":"2013-09-26","deletedIndicator":"No"},{"value":"Cabozantinib","valueDescription":"XL184 (Cabozantinib-S-malate)","ValueMeaning":{"publicId":"3134357","version":"1","preferredName":"XL184 (Cabozantinib-S-malate)","longName":"3134357","preferredDefinition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabozantinib S-malate","conceptCode":"C97938","definition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F391D7A-EA3F-2C4D-E040-BB89AD4302AD","latestVersionIndicator":"Yes","beginDate":"2010-09-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E75490CB-9EAE-9630-E040-BB89AD430967","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-26","modifiedBy":"ONEDATA","dateModified":"2013-09-26","deletedIndicator":"No"},{"value":"Enzalutamide","valueDescription":"Selective Androgen Receptor Modulator MDV3100 (Enzalutamide)","ValueMeaning":{"publicId":"3441945","version":"1","preferredName":"Selective Androgen Receptor Modulator MDV3100 (Enzalutamide)","longName":"3441945","preferredDefinition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F3C92-EDA4-5858-E040-BB89AD4304B3","latestVersionIndicator":"Yes","beginDate":"2012-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E75472A6-B2C4-BB47-E040-BB89AD4360A2","beginDate":"2012-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-26","modifiedBy":"ONEDATA","dateModified":"2013-09-26","deletedIndicator":"No"},{"value":"Apalutamide","valueDescription":"Apalutamide","ValueMeaning":{"publicId":"5811375","version":"1","preferredName":"Apalutamide","longName":"5811375","preferredDefinition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apalutamide","conceptCode":"C92574","definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2E845A-26D5-6A9B-E053-F662850ACCDA","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F2E845A-26EE-6A9B-E053-F662850ACCDA","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"ONEDATA","dateModified":"2017-05-10","deletedIndicator":"No"},{"value":"Galeterone","valueDescription":"Galeterone","ValueMeaning":{"publicId":"5811373","version":"1","preferredName":"Galeterone","longName":"5811373","preferredDefinition":"An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Galeterone","conceptCode":"C84866","definition":"An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2E845A-26AF-6A9B-E053-F662850ACCDA","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F2E845A-26C8-6A9B-E053-F662850ACCDA","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"ONEDATA","dateModified":"2017-05-10","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5FAC7F-86E1-715C-E053-F662850A4470","beginDate":"2017-10-12","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60CA498D-8FEC-3D57-E053-F662850A4B5A","beginDate":"2017-12-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-20","modifiedBy":"ONEDATA","dateModified":"2017-12-20","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60CA498D-9000-3D57-E053-F662850A4B5A","beginDate":"2017-12-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-20","modifiedBy":"ONEDATA","dateModified":"2017-12-20","deletedIndicator":"No"},{"value":"Etoposide","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60CA498D-9014-3D57-E053-F662850A4B5A","beginDate":"2017-12-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-20","modifiedBy":"ONEDATA","dateModified":"2017-12-20","deletedIndicator":"No"},{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"5544728","version":"1","preferredName":"Cisplatin","longName":"5544728","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FCC725E-178D-054A-E053-F662850A831B","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"ZHANGW","dateCreated":"2016-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60CA498D-9028-3D57-E053-F662850A4B5A","beginDate":"2017-12-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-20","modifiedBy":"ONEDATA","dateModified":"2017-12-20","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60CA498D-903C-3D57-E053-F662850A4B5A","beginDate":"2017-12-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-20","modifiedBy":"ONEDATA","dateModified":"2017-12-20","deletedIndicator":"No"},{"value":"Strontium-89","valueDescription":"Strontium Chloride Sr-89","ValueMeaning":{"publicId":"5920617","version":"1","preferredName":"Strontium Chloride Sr-89","longName":"5920617","preferredDefinition":"The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strontium Chloride Sr-89","conceptCode":"C1238","definition":"The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5656A68A-62CF-6DA9-E053-F662850AFA9C","latestVersionIndicator":"Yes","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5656A68A-62E8-6DA9-E053-F662850AFA9C","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"ONEDATA","dateModified":"2017-08-09","deletedIndicator":"No"},{"value":"Radium-223 Dichloride","valueDescription":"Radium Chloride Ra-223","ValueMeaning":{"publicId":"3788420","version":"1","preferredName":"Radium Chloride Ra-223","longName":"3788420","preferredDefinition":"A radiopharmaceutic of short-lived radium-223 with potential anti-tumor activity. Radium preferentially binds to and accumulates in bone tissue. The radioisotope radium-223 may kill bone cancer cells through the local emission of high energy alpha particles, thereby potentially decreasing tumor progression in the skeleton.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radium Ra 223 Dichloride","conceptCode":"C62535","definition":"A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB3D-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5656A68A-62FC-6DA9-E053-F662850AFA9C","beginDate":"2017-08-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-08-09","modifiedBy":"ONEDATA","dateModified":"2017-08-09","deletedIndicator":"No"},{"value":"Deslorelin","valueDescription":"Deslorelin","ValueMeaning":{"publicId":"3439554","version":"1","preferredName":"Deslorelin","longName":"3439554","preferredDefinition":"A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deslorelin","conceptCode":"C38709","definition":"A synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone (GnRH) with potential antineoplastic activity. Deslorelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Continuous, prolonged administration of goserelin in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1AAB-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Corrected spelling of agent and added concept_11.06.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5D56568E-3F26-26D6-E053-F662850A5BA8","beginDate":"2012-04-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-06","modifiedBy":"ONEDATA","dateModified":"2017-11-06","deletedIndicator":"No"},{"value":"Seviteronel","valueDescription":"Seviteronel","ValueMeaning":{"publicId":"6024682","version":"1","preferredName":"Seviteronel","longName":"6024682","preferredDefinition":"An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seviteronel","conceptCode":"C113652","definition":"An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D54FB97-555F-405A-E053-F662850A970C","latestVersionIndicator":"Yes","beginDate":"2017-11-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5D54FB97-5578-405A-E053-F662850A970C","beginDate":"2017-11-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-06","modifiedBy":"ONEDATA","dateModified":"2017-11-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3439552","version":"1","preferredName":"Prostate Carcinoma Agent Name","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C4863:C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1A87-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"ONEDATA","dateModified":"2012-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-C9A5-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"HARTLEYG","dateModified":"2017-12-20","changeDescription":"v2.0 replaces retired v1.0 with an increase in field length from 20 to 50 characters.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"History of drugs/therapies","type":"Preferred Question Text","description":"History of drugs/therapies","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DF80A1B1-CB9E-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"REEVESD","dateModified":"2015-04-14","changeDescription":"Curated to support Duke University clinical trial. v2.0 replaces v1.0 with expanded VD from 20 to 50 characters.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}